Cargando…

Prevalence of Drug-Related Problems and Cost-Savings Opportunities in Medicaid High Utilizers Identified by a Pharmacist-Run Drug Regimen Review Center

BACKGROUND: Despite numerous reports of state Medicaid drug utilization review (DUR) programs, little data are available about the prevalence of drug related problems (DRPs) in Medicaid patients. A university-based, pharmacist-run DUR program for high utilizers was created as an alternative to impos...

Descripción completa

Detalles Bibliográficos
Autores principales: LaFleur, Joanne, McBeth, Carrieann, Gunning, Karen, Oderda, Lynda, Steinvoort, Carin, Oderda, Gary M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438027/
https://www.ncbi.nlm.nih.gov/pubmed/17269846
http://dx.doi.org/10.18553/jmcp.2006.12.8.677
_version_ 1785092689240260608
author LaFleur, Joanne
McBeth, Carrieann
Gunning, Karen
Oderda, Lynda
Steinvoort, Carin
Oderda, Gary M.
author_facet LaFleur, Joanne
McBeth, Carrieann
Gunning, Karen
Oderda, Lynda
Steinvoort, Carin
Oderda, Gary M.
author_sort LaFleur, Joanne
collection PubMed
description BACKGROUND: Despite numerous reports of state Medicaid drug utilization review (DUR) programs, little data are available about the prevalence of drug related problems (DRPs) in Medicaid patients. A university-based, pharmacist-run DUR program for high utilizers was created as an alternative to imposition of a statutory limit of 7 medications per month in the Utah Medicaid program in 2002. The DUR program was designed to suggest ways that high-utilizing patients could decrease their total number of medications to 7 or fewer prior to imposition of the 7-medication limit at some time in the future. OBJECTIVES: To describe the experience in 1 Medicaid DUR program and to report the prevalence of DRPs and cost-saving opportunities (CSOs) among a population of Medicaid recipients who were high utilizers of prescription drugs. METHODS: DRPs were identified by 5 clinical pharmacists employed by the Drug Regimen Review Center (DRRC) in Salt Lake City. The purpose of the center was to provide drug therapy review services for a select number of Utah Medicaid recipients (200-300 per month) who exceeded a 7-medication limit during the calendar years 2003 and 2004. RESULTS: Out of 391,890 eligible Medicaid recipients, 242,411 (62%) received at least 1 medication, and 16,958 (4.3%) exceeded the 7-medication limit during the review period. Of those exceeding the limit, the DRRC reviewed a total of 3,706 (21.9%) patients, representing the highest utilizers by volume of medication. The prevalence of DRPs considered clinically important in the review cohort was 79.7% of patients, including therapeutic duplications in 54.6% of patients, dose form optimization in 29.7%, and inappropriate uncoordinated care in 25.3%. The average pharmacy cost per month for patients with at least 1 DRP was $1,081; by contrast, the average pharmacy cost per month for all other patients receiving at least 1 prescription was $91. CONCLUSIONS: Approximately 4% of Medicaid recipients exceeded the 7-medication monthly limit. Among the 22% highest utilizers in this group, 48% of nursing home residents and 87% of ambulatory recipients had at least 1 DRP, or an overall rate of 80% of high-use Medicaid recipients or as much as 3.2% of the Medicaid population.
format Online
Article
Text
id pubmed-10438027
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-104380272023-08-21 Prevalence of Drug-Related Problems and Cost-Savings Opportunities in Medicaid High Utilizers Identified by a Pharmacist-Run Drug Regimen Review Center LaFleur, Joanne McBeth, Carrieann Gunning, Karen Oderda, Lynda Steinvoort, Carin Oderda, Gary M. J Manag Care Pharm Contemporary Subjects BACKGROUND: Despite numerous reports of state Medicaid drug utilization review (DUR) programs, little data are available about the prevalence of drug related problems (DRPs) in Medicaid patients. A university-based, pharmacist-run DUR program for high utilizers was created as an alternative to imposition of a statutory limit of 7 medications per month in the Utah Medicaid program in 2002. The DUR program was designed to suggest ways that high-utilizing patients could decrease their total number of medications to 7 or fewer prior to imposition of the 7-medication limit at some time in the future. OBJECTIVES: To describe the experience in 1 Medicaid DUR program and to report the prevalence of DRPs and cost-saving opportunities (CSOs) among a population of Medicaid recipients who were high utilizers of prescription drugs. METHODS: DRPs were identified by 5 clinical pharmacists employed by the Drug Regimen Review Center (DRRC) in Salt Lake City. The purpose of the center was to provide drug therapy review services for a select number of Utah Medicaid recipients (200-300 per month) who exceeded a 7-medication limit during the calendar years 2003 and 2004. RESULTS: Out of 391,890 eligible Medicaid recipients, 242,411 (62%) received at least 1 medication, and 16,958 (4.3%) exceeded the 7-medication limit during the review period. Of those exceeding the limit, the DRRC reviewed a total of 3,706 (21.9%) patients, representing the highest utilizers by volume of medication. The prevalence of DRPs considered clinically important in the review cohort was 79.7% of patients, including therapeutic duplications in 54.6% of patients, dose form optimization in 29.7%, and inappropriate uncoordinated care in 25.3%. The average pharmacy cost per month for patients with at least 1 DRP was $1,081; by contrast, the average pharmacy cost per month for all other patients receiving at least 1 prescription was $91. CONCLUSIONS: Approximately 4% of Medicaid recipients exceeded the 7-medication monthly limit. Among the 22% highest utilizers in this group, 48% of nursing home residents and 87% of ambulatory recipients had at least 1 DRP, or an overall rate of 80% of high-use Medicaid recipients or as much as 3.2% of the Medicaid population. Academy of Managed Care Pharmacy 2006-10 /pmc/articles/PMC10438027/ /pubmed/17269846 http://dx.doi.org/10.18553/jmcp.2006.12.8.677 Text en Copyright © 2006, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Contemporary Subjects
LaFleur, Joanne
McBeth, Carrieann
Gunning, Karen
Oderda, Lynda
Steinvoort, Carin
Oderda, Gary M.
Prevalence of Drug-Related Problems and Cost-Savings Opportunities in Medicaid High Utilizers Identified by a Pharmacist-Run Drug Regimen Review Center
title Prevalence of Drug-Related Problems and Cost-Savings Opportunities in Medicaid High Utilizers Identified by a Pharmacist-Run Drug Regimen Review Center
title_full Prevalence of Drug-Related Problems and Cost-Savings Opportunities in Medicaid High Utilizers Identified by a Pharmacist-Run Drug Regimen Review Center
title_fullStr Prevalence of Drug-Related Problems and Cost-Savings Opportunities in Medicaid High Utilizers Identified by a Pharmacist-Run Drug Regimen Review Center
title_full_unstemmed Prevalence of Drug-Related Problems and Cost-Savings Opportunities in Medicaid High Utilizers Identified by a Pharmacist-Run Drug Regimen Review Center
title_short Prevalence of Drug-Related Problems and Cost-Savings Opportunities in Medicaid High Utilizers Identified by a Pharmacist-Run Drug Regimen Review Center
title_sort prevalence of drug-related problems and cost-savings opportunities in medicaid high utilizers identified by a pharmacist-run drug regimen review center
topic Contemporary Subjects
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438027/
https://www.ncbi.nlm.nih.gov/pubmed/17269846
http://dx.doi.org/10.18553/jmcp.2006.12.8.677
work_keys_str_mv AT lafleurjoanne prevalenceofdrugrelatedproblemsandcostsavingsopportunitiesinmedicaidhighutilizersidentifiedbyapharmacistrundrugregimenreviewcenter
AT mcbethcarrieann prevalenceofdrugrelatedproblemsandcostsavingsopportunitiesinmedicaidhighutilizersidentifiedbyapharmacistrundrugregimenreviewcenter
AT gunningkaren prevalenceofdrugrelatedproblemsandcostsavingsopportunitiesinmedicaidhighutilizersidentifiedbyapharmacistrundrugregimenreviewcenter
AT oderdalynda prevalenceofdrugrelatedproblemsandcostsavingsopportunitiesinmedicaidhighutilizersidentifiedbyapharmacistrundrugregimenreviewcenter
AT steinvoortcarin prevalenceofdrugrelatedproblemsandcostsavingsopportunitiesinmedicaidhighutilizersidentifiedbyapharmacistrundrugregimenreviewcenter
AT oderdagarym prevalenceofdrugrelatedproblemsandcostsavingsopportunitiesinmedicaidhighutilizersidentifiedbyapharmacistrundrugregimenreviewcenter